These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 8095331)

  • 21. Drug therapy of peptic ulcer disease.
    Ching CK; Lam SK
    Br J Hosp Med; 1995 Jul 12-Aug 15; 54(2-3):101-6. PubMed ID: 7551483
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders.
    Langtry HD; Wilde MI
    Drugs; 1997 Sep; 54(3):473-500. PubMed ID: 9279507
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acid pump blockers: what are their current therapeutic roles?
    Arens MJ; Dent J
    Baillieres Clin Gastroenterol; 1993 Mar; 7(1):95-128. PubMed ID: 8097414
    [No Abstract]   [Full Text] [Related]  

  • 24. Cost-effectiveness of treatment regimens for the eradication of Helicobacter pylori in duodenal ulcer.
    Vakil N; Fennerty MB
    Am J Gastroenterol; 1996 Feb; 91(2):239-45. PubMed ID: 8607487
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of omeprazole in the treatment of refractory acid-related diseases in childhood: endoscopic healing and twenty-four-hour intragastric acidity.
    Kato S; Ebina K; Fujii K; Chiba H; Nakagawa H
    J Pediatr; 1996 Mar; 128(3):415-21. PubMed ID: 8774516
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Management of nonsteroidal anti-inflammatory drug-induced gastroduodenal disease by acid suppression.
    Lad R; Armstrong D
    Can J Gastroenterol; 1999 Mar; 13(2):135-42. PubMed ID: 10203432
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lansoprazole. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders.
    Spencer CM; Faulds D
    Drugs; 1994 Sep; 48(3):404-30. PubMed ID: 7527761
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reflux esophagitis.
    Tytgat GN; Nio CY; Schotborgh RH
    Scand J Gastroenterol Suppl; 1990; 175():1-12. PubMed ID: 1978403
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders.
    Barradell LB; Faulds D; McTavish D
    Drugs; 1992 Aug; 44(2):225-50. PubMed ID: 1382017
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Eradication of Helicobacter pylori prevents recurrence of ulcer after simple closure of duodenal ulcer perforation: randomized controlled trial.
    Ng EK; Lam YH; Sung JJ; Yung MY; To KF; Chan AC; Lee DW; Law BK; Lau JY; Ling TK; Lau WY; Chung SC
    Ann Surg; 2000 Feb; 231(2):153-8. PubMed ID: 10674604
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Gastric lesion caused by NSAID and inflammation due to Helicobacter pylori. Is there potentiation or attenuation?].
    Lanas Arbeloa A; Serrano Aulló MT
    Gastroenterol Hepatol; 1998 Jan; 21 Suppl 1():20-4. PubMed ID: 9549198
    [No Abstract]   [Full Text] [Related]  

  • 32. Rabeprazole: a review of its use in acid-related gastrointestinal disorders.
    Langtry HD; Markham A
    Drugs; 1999 Oct; 58(4):725-42. PubMed ID: 10551440
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Therapy of reflux esophagitis].
    Berges W; Wienbeck M
    Z Gastroenterol; 1993 Nov; 31 Suppl 5():15-7. PubMed ID: 7910994
    [No Abstract]   [Full Text] [Related]  

  • 34. Use of proton-pump inhibitors in complicated ulcer disease and upper gastrointestinal tract bleeding.
    Howden CW
    Am J Health Syst Pharm; 1999 Dec; 56(23 Suppl 4):S5-11. PubMed ID: 10597118
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacological effects of metronidazole+tetracycline+bismuth subcitrate versus omeprazole+amoxycillin+bismuth subcitrate in Helicobacter pylori-related gastritis and peptic ulcer disease.
    Park KN; Hahm JS; Kim HJ
    Eur J Gastroenterol Hepatol; 1994 Dec; 6 Suppl 1():S103-7. PubMed ID: 7735924
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Histamine H2-receptor antagonists in peptic ulcer disease. Efficacy in healing peptic ulcers.
    Deakin M; Williams JG
    Drugs; 1992 Nov; 44(5):709-19. PubMed ID: 1280563
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lansoprazole: a comprehensive review.
    Zimmermann AE; Katona BG
    Pharmacotherapy; 1997; 17(2):308-26. PubMed ID: 9085323
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current trends in the pharmacotherapy for peptic ulcer disease.
    Hixson LJ; Kelley CL; Jones WN; Tuohy CD
    Arch Intern Med; 1992 Apr; 152(4):726-32. PubMed ID: 1558429
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pathogenesis and treatment of acid peptic disorders: comparison of proton pump inhibitors with other antiulcer agents.
    Sanders SW
    Clin Ther; 1996; 18(1):2-34; discussion 1. PubMed ID: 8851451
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Atypical and aggressive upper gastrointestinal ulceration associated with aspirin abuse.
    Hirschowitz BI; Lanas A
    J Clin Gastroenterol; 2002; 34(5):523-8. PubMed ID: 11960062
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.